IMR Press / EJGO / Volume 27 / Issue 3 / pii/2006160

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Effective chemoradiotherapy protocol with 5-fluorouracil for cervical squamous cell carcinoma in vitro

Show Less
1 Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan
2 Department of Physiology, Wakayama Medical University, Wakayama, Japan
Eur. J. Gynaecol. Oncol. 2006, 27(3), 243–246;
Published: 10 June 2006

Purpose of investigation: 5-Fluorouracil (5FU) is frequently used in concurrent chemoradiotherapy for patients with advanced cervical cancer, although its optimal chemoradiotherapy protocol has not yet been established. In search of an optimal chemora­diotherapy protocol, some in vitro experiments were carried out. Methods: The radiosensitive human cervical squamous cell carcinoma cell line ME180 was examined to investigate the effects of 5FU on radiosensitivity and the effects of irradiation on 5FU-sensitivity. Results: 5FU dose-dependently enhanced cellular radiosensitivity at therapeutic concentrations. Although high doses of y-ray irra­diation significantly reduced the 5FU-sensitivity, a low dose of irradiation at therapeutic doses (<2.5 Gy) had no effect on 5FU­sensitivity of the irradiated cells. Cells pretreated with 5FU eight hours before irradiation showed significantly higher 5FU-sensi­tivity than cells concurrently treated with 5FU and irradiation. In contrast, cells treated with 5FU eight hours after irradiation showed significantly lower 5FU-sensitivity than cells concurrently treated with 5FU and irradiation. Moreover, all four post-irradiation sur­viving subclones obtained from repeatedly irradiated ME180 cells showed significantly lower 5FU-sensitivity than the non-irradi­ated parent cells. Conclusion  5FU acts as a radiosensitizer for cervical squamous cell carcinoma and 5FU-sensitivity is reduced in irradiated cells. Therefore, 5FU administration immediately before irradiation may be a more effective treatment than concurrent chemoradiother­apy or post-irradiation chemotherapy with 5FU.

Cervical cancer
Squamous cell carcinoma
Back to top